The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 17, 2010

Filed:

Jun. 17, 2008
Applicants:

Trevor T. Charvat, San Jose, CA (US);

Cheng HU, Menlo Park, CA (US);

Anita Melikian, San Francisco, CA (US);

Aaron Novack, San Jose, CA (US);

Andrew M. K. Pennell, San Francisco, CA (US);

Edward J. Sullivan, San Jose, CA (US);

William D. Thomas, San Jose, CA (US);

Solomon Ungashe, Fremont, CA (US);

Penglie Zhang, Foster City, CA (US);

Jay Powers, Pacifica, CA (US);

Sreenivas Punna, Sunnyvale, CA (US);

Inventors:

Trevor T. Charvat, San Jose, CA (US);

Cheng Hu, Menlo Park, CA (US);

Anita Melikian, San Francisco, CA (US);

Aaron Novack, San Jose, CA (US);

Andrew M. K. Pennell, San Francisco, CA (US);

Edward J. Sullivan, San Jose, CA (US);

William D. Thomas, San Jose, CA (US);

Solomon Ungashe, Fremont, CA (US);

Penglie Zhang, Foster City, CA (US);

Jay Powers, Pacifica, CA (US);

Sreenivas Punna, Sunnyvale, CA (US);

Assignee:

ChemoCentryx, Inc., Mountain View, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/42 (2006.01); A61K 31/44 (2006.01); C07D 513/02 (2006.01); C07D 515/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.


Find Patent Forward Citations

Loading…